Chugai Pharmaceutical Publishes Transcript of FY2026 Q3 Financial Results Conference

Bitget2026/10/28 11:52

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Chugai Pharmaceutical’s October 27, 2026, FY2026 third-quarter results conference featured CEO Osamu Okuda and CFO Iwaaki Taniguchi.
Nine-month revenue reached JPY 1.07 trillion; core operating profit totaled JPY 536.1 billion.
Management expects to exceed its full-year forecast, with Actemra sales projected to beat expectations by more than JPY 10 billion.
ERP-related shipment front-loading boosted domestic sales by the low JPY 30 billion range; the one-time benefit will reverse in the fourth quarter.
Hemlibra’s autoinjector launch is targeted for Japan and global markets in 2027, with no material increase in the cost ratio expected.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chugai Pharmaceutical Co. Ltd. published the original content used to generate this news brief on October 28, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Chugai Pharmaceutical Publishes Transcript of FY2026 Q3 Financial Results Conference

You may also like

Crypto prices